Skip to content

Management of NAFLD through Ayurveda

Clinical Efficacy and safety of Arogyavardhini Vati and Pippalyadyasava in the management of Non-Alcoholic Fatty Liver Disease (NAFLD) –An open level prospective clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/02/040321
Enrollment
90
Registered
2022-02-15
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E889- Metabolic disorder, unspecified

Interventions

None listed

Sponsors

CCRAS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases of Grade- I&II of Non-alcoholic fatty liver disease as evident fatty infiltration on Ultrasound. Either sex aged between18- 60 years. Subjects of non-alcoholic fatty liver disease with their hepatic enzymes Willing to provide written consent and able to participate for 4 months in the study.

Exclusion criteria

Exclusion criteria: H/o habitual consumption of alcohol intake of >20g/day for women, >40g/day for men Any other identified cause of chronic liver disease The use of medication which would cause non-alcoholic fatty liver - disease e.g. tamoxifen Already taking supplementary medicine for NAFLD On anticoagulants (antiplatelet aggregators are permitted) Past history of Cardiac Arrhythmia, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. Symptomatic patients with clinical evidence of congestive cardiac failure. Subjects with concurrent Renal Dysfunction (defined as S. creatinine > 1.2 mg/dl), uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) or other concurrent severe disease. Uncontrolled Diabetes Mellitus (HbA1C >8) Known cases of HIV and AIDS, malignancy, Hepatitis B Subjects participated in any other clinical trial. Women who are planning for conception / pregnant or lactating.Any other condition which the P.I. thinks may jeopardize the study.

Design outcomes

Primary

MeasureTime frame
To assess the change in fibroscan score (Kpa) and CAP value (Kpa) or MRI-PDFFTimepoint: Baseline& 90th day

Secondary

MeasureTime frame
To assess changes in ALT, AST, Serum bilirubin, Total proteins & Alkaline Phosphatase Changes in Lipid profile Changes in HbA1C Change in BMI To measure change in Fatty Liver Index To assess any biological intolerability or adverse events during the trial period Timepoint: Baseline, 90th day

Countries

India

Contacts

Public ContactDr Banamali Das

CCRAS

banamali.d@gmail.com8249683316

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 6, 2026